Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Dose and Multiple Rising Oral Doses of BI 706321 in Healthy Japanese Male Subjects and Single Oral Dose of BI 706321 in Healthy Chinese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)
Latest Information Update: 10 Oct 2025
At a glance
- Drugs BI 706321 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 23 Sep 2025 Actual primary completion date changed from 8 Aug 2024 to 12 Aug 2022.
- 20 Aug 2024 Status changed from recruiting to discontinued.
- 02 Apr 2024 Planned End Date changed from 25 Feb 2025 to 21 Oct 2025.